Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Actualización sobre el tratamiento de la tuberculosis

  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Tuberculosis (TB) affects more than 10 million people each year. We have contested this burden with a paradoxically slow development of treatments, as compared to other infectious diseases. This review aims to update health care professionals on the last developments for the management of TB. The combination of drugs established more than 40 years ago is still adequate to cure most people affected by TB. However, with the generalisation of regimens based on rifampicin and isoniazid for (only) 6 months, resistance emerged. Resistant cases needed long treatments based on injectable drugs. Now, after an exciting decade of research, we can treat resistant TB with oral regimens based on bedaquiline, nitroimidazoles, and linezolid for (only) 6 months, and we may soon break the 6-month barrier for treatment duration. However, these improvements are not enough to end TB without an engagement of people affected and their communities to achieve adherence to treatment, transmission control, and improve socioeconomic determinants of health.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis

  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Aguiar, Ana|||0000-0001-7841-7410
  • Nara, Eva
  • Medina, Angelica
  • Molinas, Gladys
  • Tavares, Margarida|||0000-0003-4518-2197
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Ghimire, Samiksha|||0000-0002-6028-1460
  • Alfenaar, Jan-Willem C.
  • Sturkenboom, Marieke G. G.|||0000-0002-3420-0591
  • Magis-Escurra, Cecile|||0000-0001-8424-9425
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Barros, Henrique
  • Duarte, Raquel
Background: Higher than standard doses of rifampicin could improve the treatment outcome of drug-susceptible tuberculosis without compromising the safety of patients. Methods: We performed a systematic review of prospective clinical studies including adults with pulmonary and extrapulmonary TB receiving rifampicin doses above 10mg/kg/day. We extracted the data on overall adverse events (AE), hepatic AE, sputum culture conversion (SCC) at week 8, recurrence, mortality, and pharmacokinetics. We performed a Bayesian network meta-analysis (NMA) using a random-effects model. Results: In 19 studies, 2033 out of 3654 participants received rifampicin doses higher than 10mg/kg/day. The NMA showed an increased risk of overall and hepatic AE for the 40mg/kg/day dose (RR 4.8, 95% CrI 1.1; 25, and 15.00, 95% CrI 1.1; 58.0, respectively), but no other doses, including 50mg/kg/day showed such an increase. Increasing doses improved sputum culture conversion at week 8 (RR 1.3, 95% CrI 1.1; 1.7 for SCC with 35mg/kg/day). Conclusion: Optimal doses of rifampicin may be between 25 and 35mg/kg/day, but should be tailored at the individual or, at least, at the population level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy of Tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Sellarès-Nadal, Júlia|||0000-0002-0209-6494
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Burgos, Joaquín|||0000-0001-8445-3047
  • Falcó, Vicenç|||0000-0001-9626-0023
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Bañares-Sánchez, Joan
  • Prio-Ruatg, Alba
  • Martínez-Valle, Ferran
  • Kirkegaard, Cristina|||0000-0001-9035-1450
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Background: The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design: Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Efficacy of tocilizumab for hospitalized patients with COVID-19 pneumonia and high IL-6 levels: A randomized controlled trial

  • Augustin Recio, Salvador
  • Prió, Alba
  • Sellarès-Nadal, Júlia
  • Espinosa-Pereiro, Juan
  • Burgos, Joaquin
  • Falcó, Vicenç
  • Guillen-Del-Castillo, Alfredo
  • Bañares, Juan
  • Martínez-Valle, Fernando
  • Kirkegaard, Cristina
  • SÁNCHEZ-MONTALVÁ, ADRIÁN
Acute respiratory distress syndrome; COVID-19; Interleukin-6, Síndrome de dificultat respiratòria aguda; COVID-19; Interleucina-6, Síndrome de dificultad respiratoria aguda; COVID-19; Interleucina-6, Background The objective of this clinical trial is to evaluate the efficacy and safety of IL-6 driven personalized treatment strategy with tocilizumab in patients with severe COVID-19 pneumonia. Trial design Randomized, controlled, open-label, single-center trial of a tocilizumab treatment strategy in adult patients hospitalized with severe COVID-19 pneumonia and IL-6 serum levels > 40 pg/mL. Methods Patients were randomized 1:1 to receive standard of care (SOC) or SOC plus one dose of tocilizumab. The primary outcome was death or need for invasive mechanical ventilation (IMV) within 28 days after randomization. Secondary outcomes included ICU admission, days on IMV and hospital stay. A meta-analysis of clinical trials to evaluate the effect of tocilizumab on mortality and need of IMV in patients with COVID-19 pneumonia was performed. Results Sixty-two patients were included: 30 in the SOC arm and 32 in the standard-treatment plus tocilizumab arm. The primary outcome occurred in 12.9% in the tocilizumab arm and 32.3% in the SOC arm(p = 0.068). There was a trend towards fewer days on IMV (7.5 vs 19.5 days, p = 0.073) and a shorter hospital stay (4 vs 8 days, p = 0.134) in the tocilizumab group. No serious adverse events were reported. The meta-analysis revealed a RR for death or IMV of 0.83 (95% CI: 0.77–0.89) in patients receiving tocilizumab, compared to patients receiving SOC. Conclusion Tocilizumab could be effective to prevent death or IMV in patients with severe COVID-19 pneumonia and high IL-6 serum levels. Safety profile of tocilizumab does not arise major concern in patients with severe COVID19., Open Access Funding provided by Universitat Autonoma de Barcelona. This study received support of “Plataforma ISCIII de Soporte para la Investigación Clínica—SCReN (Spanish Clinical Research Network)” which is funded by ISCIII through the project sPT17/0017/0030 and PT20/00078, which are both integrated in the “Plan Estatal de I + D + I 2013–2016 y 2017–2020” and co-funded by the “ Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa””. ASM was supported by the Instituto de Salud Carlos III (Juan Rodés postdoctoral fellowship grant number JR18/00022) during the study period. JSN and JEP are supported by the Instituto de Salud Carlos III (Rio Hortega predoctoral grant numbers CM22/00262 and CM22/00246).